Ivabradin Teva B.V.

Ivabradine, the active ingredient in Ivabradin Teva B.V., is an If channel inhibitor presented as an oral dosage form for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradin Teva B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradin Teva B.V. acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic.

Chronic stable angina: reduces the frequency of angina attacks by lowering myocardial oxygen demand. Heart failure with reduced ejection fraction: decreases resting heart rate, improving ventricular filling and functional capacity.

Ivabradin Teva B.V. may cause a range of adverse reactions.

Common Side Effects: - Bradycardia: resting heart rate falls below the intended range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo: especially on standing. - Fatigue: general feeling of tiredness. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension leading to syncope. - Persistent visual impairment or retinal disorders. - Heart block or advanced atrioventricular conduction disturbances. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before prescribing Ivabradin Teva B.V., clinicians should consider several safety measures.

Assess heart rate before initiation: ensure resting heart rate is ≥ 50 bpm. Avoid use in severe hepatic impairment: drug exposure may increase markedly. Monitor for symptomatic bradycardia: discontinue if severe bradycardia occurs. Caution with concomitant beta‑blockers or digoxin: risk of excessive heart‑rate reduction. Contraindicated in patients with sick‑sinus syndrome unless a pacemaker is present. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradin Teva B.V. can interact with several medicines that affect its metabolism or cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine plasma concentrations. - Co‑administration with other bradycardic agents (beta‑blockers, digoxin): can cause excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly increase ivabradine levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine efficacy. - Antacids containing aluminium or magnesium: may impair absorption if taken simultaneously.